Brain Ischemia – Pipeline Review, 2019

Brain ischemia is the condition where, there is lack of adequate supply to the brain in order to perform metabolic activities. Brain ischemia is also referred as cerebral ischemia or cerebrovascular ischemia. Additionally, Thrombotic, Embolic and Hypoperfusion are the commonly observed types of brain ischemia. One sided body weakness, confusion or disorientation, dizziness, double vision, and slurred speech are some of the commonly observed symptoms of brain ischemia amongst others. The disease is prominently caused due to sickle cell anaemia, heart disease, blood clots, and congenital heart diseases. According to study conducted by American Heart Association in 2017, an estimated 300,000 people suffers from traumatic brain injury each year in the U.S.

At present, the brain ischemia treatment includes lifestyle change, routine exercise, and stress management. Moreover, certain drugs such as anti-platelet drugs and anticoagulants are prescribed by physicians to treat brain ischemia.

Pharmaceutical companies and academic centers & research institutes are prominently focusing on studying and developing new treatment options for the Brain ischemia. For instance; BMS-986177, which is being studied by Bristol-Myers Squibb, is currently in phase-2 clinical trials to check its efficacy and tolerability for the prevention of new ischemic stroke in patients with transient ischemic attack.

At present around 61% of the pipeline candidates for Brain ischemia are in the phase-2 and phase-3 stage. Majority of the studies have been sponsored by pharmaceutical companies and research institutes & academic centres.

Report Description

The report on ‘Brain Ischemia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Brain Ischemia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Brain Ischemia.

The report on ‘Brain Ischemia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Brain Ischemia


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Brain Ischemia


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary